SA PRO
Free Account
BIOABIOA
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
3 analysts·Low coverage
33%
Rating Distribution
Strong Buy
00%
Buy
133%
Hold
267%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 37% above analyst consensus — significant downside expected.

Bear Case
$12.00
-37%
Consensus
$12.00
-37%
Bull Case
$12.00
+-37%
Price Range3 analysts
Low
Consensus
High
$12.00
$12.00
Current Target
Current Price
$18.99
Above Target
$6.99

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 5, 2025Morgan Stanley
BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley
Target:$12.00
+5.3%from $11.40
Mar 7, 2025Morgan Stanley
BioAge Labs assumed with an Underweight at Morgan Stanley
Target:$5.00
+9.9%from $4.55
Dec 9, 2024Jefferies
Jefferies Downgrades BioAge Labs Inc (BIOA) to Hold
Target:$7.00
+50.5%from $4.65
Oct 21, 2024Citigroup
BioAge Labs initiated with a Buy at Citi
Target:$45.00
+88.6%from $23.86
Oct 21, 2024Jefferies
Jefferies Starts BioAge Labs Inc (BIOA) at Buy
Target:$42.00
+76.0%from $23.86
Oct 21, 2024Morgan Stanley
Morgan Stanley Starts BioAge Labs Inc (BIOA) at Overweight
Target:$40.00
+67.6%from $23.86

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance